Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients
About this item
Full title
Author / Creator
Publisher
China (Republic : 1949- ): Elsevier Taiwan
Journal title
Language
English
Formats
Publication information
Publisher
China (Republic : 1949- ): Elsevier Taiwan
Subjects
More information
Scope and Contents
Contents
Abstract Lamivudine, telbivudine, and entecavir are the first-line drugs covered by the Taiwan National Health Insurance as 3-year treatments for patients with chronic hepatitis B virus (HBV), but the optimal treatment duration of each remains unclear. We aimed to detect HBV treatment-cessation durability, and compare the predictors in patients wit...
Alternative Titles
Full title
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_cf4bf80647bd4525a5b56c766ec1e69d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cf4bf80647bd4525a5b56c766ec1e69d
Other Identifiers
ISSN
1607-551X
E-ISSN
2410-8650
DOI
10.1016/j.kjms.2015.11.005
